Category: News

Post

Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. Motif Bio plc (AIM/NASDAQ: MTFB) (“Motif Bio”, or “the Group”),...

September 25, 2018September 25, 2018by In News
Post

ContraFect to Present at Two Upcoming Investor Conferences

YONKERS, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chairman and Chief Executive Officer, will present at two upcoming investor conferences. The Company will...

September 20, 2018September 20, 2018by In News
Post

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7, 2018 San Francisco, CA  USA Iclaprim data will be presented at the conference in a poster,...

September 20, 2018September 20, 2018by In News
Post

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

Company remains on track to announce top-line results in Q4 2018 YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has completed enrollment in the Phase 2 clinical trial...

September 6, 2018September 6, 2018by In News
Post

Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference

Iclaprim overview presented in State of the Art Lecture Safety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycin Surveillance data confirm in vitro activity of iclaprim against wide variety of Gram-positive bacteria, including drug-resistant strains NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a...

September 5, 2018September 5, 2018by In News
Post

ContraFect to Present at Two Upcoming Investor Conferences

YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that senior management will present at two upcoming investor conferences. The Company will provide a corporate overview at the Baird Global Healthcare...

Post

ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of data on its lead drug candidate, CF-301 (exebacase), at the European Society for Clinical Microbiology and Infectious Diseases...

Post

Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference

NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/American Society For Microbiology (ASM) Conference on Drug Development to Meet the Challenge of...